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The accurate detection of severe acute respiratory syndrome–coronavirus 2 (SARS-CoV-2)
is essential for the diagnosis of coronavirus disease 2019 (COVID-19). We compared the
quantitative RT-PCR results between nasopharyngeal swabs and saliva specimens.
Methods
A COVID-19 outbreak occurred on a cruise ship at Nagasaki port, Japan. We obtained 123
nasopharyngeal swabs and saliva each from asymptomatic or mild patients in the late
phase of infection.
Results
The intervals from the diagnosis to the sampling were 25.5 days for nasopharyngeal swabs
and 28.9 days for saliva. The positive rate was 19.5% (24/123) for nasopharyngeal swabs
and 38.2% (47/123) for saliva (P = 0.48). The quantified viral copies (mean ± SEM copies/
5 μl) were 9.3±2.6 in nasopharyngeal swabs and 920±850 in saliva (P = 0.0006).
Conclusions
The advantages of saliva specimens include positive rate improvement and accurate viral
load detection. Saliva may be used as a reliable sample for SARS-CoV-2 detection.
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Introduction
The global outbreak of the coronavirus disease 2019 (COVID-19) caused by severe acute respi-
ratory syndrome–coronavirus 2 (SARS-CoV-2) has been the biggest threat for the global com-
munity since its first report in late 2019 [1, 2]. Precise and widely available diagnostic testing is
crucial in combating COVID-19. Furthermore, early viral detection from asymptomatic
patients is crucial in reducing transmission [3]. To date, nucleic acid amplification assays
using polymerase chain reaction (PCR) have been accepted as a standard method for detection
of SARS-CoV-2. Nasopharyngeal swabs are generally the recommended specimen [4], though
several problems exist especially during sample collection. First, it can lead to potential expan-
sion of infection. A number of suspected patients are inevitably in contact with each other and
healthcare workers at the test site. In order to avoid exposure, healthcare workers are required
to wear personal protective equipment (PPE) [5, 6], of which, the broad distribution and avail-
ability is often a challenge especially before upcoming outbreaks. Second, it is invasive and
causes discomfort to the tested person [7]. Consequently, a serial repeated test is not desirable
to monitor the viral load. Third, the healthcare workers are required to receive training in
order to ascertain the quality of specimen [8]. Though a well-trained healthcare worker may
obtain a specimen from the desired nasopharynx in a limited amount time and difficult posi-
tion, training and experience are required for every essential healthcare workers. For those rea-
sons, simple, safe-to-obtain and reproducible specimens are needed.
To acquire specimens, saliva is spat into a bottle without discomfort, pain, or danger and
with a minimum exposure to other transmittable patients. Further, the sampling does not
require any technique or skills. In a previous study [9], saliva demonstrated high concordance
with nasopharyngeal specimens for detecting respiratory viruses, including coronaviruses. In
recent studies comparing saliva and nasopharyngeal specimen for the detection of SARS-CoV-
2, saliva was reported to be more sensitive than nasopharyngeal specimens for patients with
severe COVID-19 [10]. In addition, SARS-CoV-2 has consistently been detected in the saliva
[11]. However, the comparison of viral detection efficiency between nasopharyngeal swabs
and saliva in the late phase of asymptomatic to mild COVID-19 patients remains unclear.
In this study a number of people were diagnosed with COVID-19 on a large cruise ship.
The ship arrived at Nagasaki port on January 29, 2020 for the purpose of supplying materials.
On April 20, 2020 one person among the 623 crew members was diagnosed with COVID-19.
Following this, the infection spread and a total of 144 patients were diagnosed with laboratory-
confirmed infection of SARS-CoV-2 using nasopharyngeal swab specimens. Some of the
patients with moderate to severe symptoms were transferred to the hospitals to receive
advanced treatment, while others with asymptomatic or mild symptoms remained on the ship
or were isolated in compartments. The health condition of every crew member was closely
monitored, and a series of nasopharyngeal swab tests were conducted till negative results were
obtained. In addition, saliva specimens were collected from the crew members at single arbi-
trary times during their stay on the ship.
We aimed to compare the positive rate and viral load of SARS-CoV-2 between nasopharyn-




A series of nasopharyngeal swab and saliva samples were obtained from COVID-19 patients
who had been diagnosed by RT-PCR or loop-mediated isothermal amplification (LAMP). The
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days of the diagnosis were defined as day 1, and the durations from day 1 to each sample col-
lection were recorded. Nasopharyngeal samples were obtained by a group of experienced phy-
sicians using sterile flocked swabs. Saliva samples were self-collected by spitting directly into a
sterile tube, immediately after waking up, prior to eating or drinking. The samples were imme-
diately transported to the laboratory department of Nagasaki university hospital and pro-
ceeded to nucleic acid amplification assays.
This study was approved by the Institutional Review Board of Nagasaki University Hospital
(20061701). The consent was not obtained since the data were analyzed anonymously.
SARS-CoV-2 detection
Nucleic acid amplification assays were conducted following manual published by the National
Institute of Infectious Diseases (NIID) [12]. Total nucleic acids were extracted from nasopha-
ryngeal swab samples using MagMAX-96 for Microarrays Total RNA Iolation Kit, and saliva
samples using the MagMAX Viral/Pathogen Nucleic Acid Isolation kit (ThermoFisher Scien-
tific) following the manufacturer’s protocol, respectively. 200 μL of saliva specimen and a
whole nasopharyngeal swab were eluted into 100 μl of elution buffer, respectively. Time and
effort required for sample preparation did not differ significantly between these two sample
types. For SARS-CoV-2 RNA detection, 5 μl of RNA template was tested, using real-time
reverse transcription (RT)-PCR primer (forward AAATTTTGGGGACCAGGAAC, reverse
TGGCAGCTGTGTAGGTCAAC) /probe (5’-FAM- ATGTCGCGCATTGGCATGGA-BHQ1-
3’) sets for 2019-nCoV_N2. PCR was conducted using Thunderbird probe one-step
qRT-PCR Kit (TOYOBO) and a Rotor-Gene Q 5plex HRM System (QIAGEN). The PCR pro-
gram consisted of 95˚C for 5 min followed by 50 cycles of 95˚C for 10 s and 60˚C for 30 s.
Viral copies were quantified using a standard curve of a 10-fold serial dilution of RNA tran-
scripts provided by the NIID. Viral load was expressed as copies/5 μl.
Statistical analysis
All data were analyzed using Prism ver. 7.0e (GraphPad Software). A P value of<0.05 was con-
sidered to indicate a statistically significant difference.
Results
Sampling information
A total of 247 nasopharyngeal swab and 123 saliva specimens were obtained from 123 COVID-
19 patients. The number of samples and timepoints are shown in S1 Fig. Among them, 123 pairs
of nasopharyngeal swabs and saliva specimens each from 123 patients were matched (Fig 1) and
included in the following analysis. The result of a nasopharyngeal swab sample obtained at the
nearest date to that of the saliva sample was chosen to draw a comparison. The intervals from the
diagnosis to the sampling were 25.5 days for nasopharyngeal swabs and 28.9 days for saliva. For
110 of the 123 cases (89.4%; nasopharyngeal swabs and saliva specimen pairs), nasopharyngeal
swab samples were collected earlier than saliva specimens, with a median gap of 2 days.
Quantitative result concordance between nasopharyngeal swab and saliva
The number of positive and negative samples are shown in Table 1. The overall concordance rate
was 60.2% (74/123). In the group with positive result of nasopharyngeal swab, 45.8% (11/24) of
saliva samples were positive, whereas only 23.4% (11/47) nasopharyngeal swab samples were pos-
itive among the group with positive result of saliva. The positive rate of each specimen was 19.5%
(24/123) for nasopharyngeal swab and 38.2% (47/123) for saliva (P = 0.48, Fisher’s exact test).
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Results of quantification (qRT-PCR)
Quantitated viral copies including all of the samples are shown in timeline in S2 Fig. Matched
comparisons of quantitated viral copies on the timeline are shown in Fig 2. Matched compari-
sons of quantitated viral copies were analyzed. Increased viral copies were detected in saliva
samples (Fig 3 and S3A, S3B Fig). With mean viral copies ± SEM of 9.3 ± 2.6 copies/5 μl
detected in nasopharyngeal swabs and 9.2 × 102 ± 8.5 × 102 copies/5 μl detected in saliva speci-
mens (P = 0.0006, Wilcoxon matched-pairs signed rank test). Among the 123 matched-pairs,
increased viral copies were detected in saliva specimens for 44 pairs (35.8%), while increased
viral copies were detected in nasopharyngeal swabs for 16 pairs (11.1%) (Fig 4). The viral cop-
ies of the rest 63 pairs (51.2%) were undetectable.
Discussion
In this study the advantages of saliva specimens in detecting SARS-CoV-2 were demonstrated.
Wyllie et al. [10] reported increased sensitivity of the saliva specimens compared to that of
the nasopharyngeal swab specimens for severe COVID-19 patients in early phase of 1 to 5
Fig 1. The numbers of matched nasopharyngeal and saliva samples. The numbers of tested samples are shown as light color and positive result as dark.
https://doi.org/10.1371/journal.pone.0252964.g001
Table 1. The number of SARS-CoV-2 RT-PCR results for nasopharyngeal swab and saliva.
saliva total
+ –
nasopharyngeal swab + 11 13 24
– 36 63 99
total 47 76 123
The positive/negative numbers of PCR result for each specimen are shown.
https://doi.org/10.1371/journal.pone.0252964.t001
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days, 6 to 10 days, and 11 or more days after the diagnosis. They also reported continuous viral
detection in saliva specimens. Our results add important findings to saliva specimen’s high
sensitivity even in late phase of asymptomatic to mild COVID-19 patients. In this pandemic,
SARS-CoV-2 PCR test is performed not only for disease diagnosis but for incidence surveil-
lance. In fact, the Japanese Government is conducting a surveillance to monitor COVID-19
incidence using saliva specimen. High sensitivity of saliva can be useful in detecting SARS-
CoV-2 in surveillance situation. In addition, persistent shedding virus is helpful in obtaining
sample for further examination, like detecting variant of concern / interest or whole genome
sequencing for phylogenetic analysis. Recent systematic reviews indicate comparable sensitiv-
ity and specificity of saliva specimen compared to nasopharyngeal specimens [13, 14], support-
ing economic advantage and expansion of testing access. In our study, SARS-CoV-2 was
detectable in 38.2% of saliva specimens and in 19.5% of the nasopharyngeal swabs. These
results indicate that, overall, saliva specimens are more sensitive than nasopharyngeal swabs
for the detection of SARS-CoV-2 from asymptomatic or mild COVID-19 patients. Some
patients had viral loads below the detection limit of saliva samples, with a corresponding naso-
pharyngeal swab showing a positive result. However, among the 47 patients with positive saliva
samples, only 23.4% (11/47) of saliva samples and nasopharyngeal swabs were positive simulta-
neously, which indicates an increased detection rate for saliva compared to that for nasopha-
ryngeal swabs.
Fig 2. The quantitated virus copies of matched nasopharyngeal swab and saliva on timeline.
https://doi.org/10.1371/journal.pone.0252964.g002
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Increased viral copies were also demonstrated in saliva samples in a recent report [10].
Angiotensin-converting enzyme II (ACE2) is the cell surface receptor of the host for SARS-
CoV-2 cell invasion [15]. ACE2 expression in salivary glands and on the tongue has been
reported [16], which supports its role as an invasion cue. Since droplets generated by saliva are
considered to be infectious [16], viral detection from saliva may support its infectivity. How-
ever, further studies are required to investigate whether these virus detected from the saliva
samples are infectious [11].
Though saliva specimens are considered to be an infectious source, the virus may be con-
tained, with less chance of transmission to healthcare workers. In addition, saliva sampling
does not induce sneezing, which increases the risks of infection, as nasopharyngeal swabbing
does.
There are several limitations in this study. First, the samples were not obtained at the same
time. Due to the circumstances and the chaos of the outbreak on a closed ship, collection of
each sample at the exact same time proved to be difficult. Therefore, there may be a possibility
that the viral load reflects a different phase of infection. However, in most cases (110/123), the
saliva samples were collected later than the nasopharyngeal swab samples. That is, the higher
positive rate and virus loads were demonstrated in saliva samples obtained at the later timing,
which are considered to contain decreasing viral load. Higher viral load detected from saliva
Fig 3. The virus copies of paired samples (n = 123) were compared and analyzed by Wilcoxon matched-pairs signed rank test.
https://doi.org/10.1371/journal.pone.0252964.g003
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samples obtained later than nasopharyngeal swab might reflect viral shedding. Though further
studies are required to this speculation, statistically higher viral load was observed from saliva
as clinical laboratory test in this study, which we believe to have a potential of contribution to
more sensitive detection of COVID-19 in clinical setting. Moreover, our finding provides fur-
ther information to clinicians that a few days gap in obtaining specimens is acceptable. In com-
batting COVID-19 cluster in similar cases such as our case, with limited medical staffs and
resources, simultaneous sampling can sometimes be difficult. Our result enables clinicians to
develop more flexible strategy in confused setting. Second, this study does not include moder-
ate to severe COVID-19 patients. Since this study was conducted using specimens collected
Fig 4. The paired quantitated virus copies of nasopharyngeal swab and saliva on scatter plot (n = 123).
https://doi.org/10.1371/journal.pone.0252964.g004
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from the crew members of a cruise ship, where medical support is not adequately provided,
patients who required advanced care could not be included. Further clinical studies are war-
ranted to clarify the comparison between specimens based on the severities and phases of
COVID-19. Third, the samples analyzed in this study were obtained after the first diagnosis of
each patient. As the patients included in this study remained on the ship, these tests were con-
ducted to re-affirm negative results. Nasopharyngeal specimens were thus obtained 25.5 days
and saliva 28.9 days after the first diagnosis. Further studies are required to determine the
sequential dynamics of the viral load from these specimens.
Conclusion
In this study, we demonstrated that saliva specimens were superior to nasopharyngeal swab
specimens for the detection of SARS-CoV-2 in the late phase of asymptomatic or mildly symp-
tomatic COVID-19 patients. The saliva specimen may be used as a reliable option for the rapid
viral detection of SARS-CoV-2.
Supporting information
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